Antiretroviral resistance in HIV: Difference between revisions
From IDWiki
Content deleted Content added
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
* |
*Genotyping sequences reverse transcriptase, integrase, and protease |
||
* |
*Resistance point mutations names as wild-type amino acid, position, and mutant amino acid (e.g. K '''103''' N) |
||
* |
*Bulk sequencing can only detect mutations that represent >20% of HIV |
||
{| class="wikitable" |
{| class="wikitable" |
||
! |
!Drug |
||
! |
!Mutation |
||
! |
!Notes |
||
|- |
|- |
||
! colspan=3 | |
! colspan="3" |NRTIs |
||
|- |
|- |
||
| rowspan=7 | |
| rowspan="7" |69 insertion complex multi-NRTI resistance |
||
| |
|M '''41''' '''L''' |
||
| |
| |
||
|- |
|- |
||
| |
|A '''62''' '''V''' |
||
| |
| |
||
|- |
|- |
||
| |
|* '''69''' '''insert''' |
||
| |
| |
||
|- |
|- |
||
| |
|K '''70''' '''R''' |
||
| |
| |
||
|- |
|- |
||
| |
|L '''210''' '''W''' |
||
| |
| |
||
|- |
|- |
||
| |
|T '''215''' '''Y F''' |
||
| |
| |
||
|- |
|- |
||
| |
|K '''219''' '''Q E''' |
||
| |
| |
||
|- |
|- |
||
| rowspan=5 | |
| rowspan="5" |151 complex multi-NRTI resistance |
||
| |
|A '''62''' '''V''' |
||
| |
| |
||
|- |
|- |
||
| |
|V '''75''' '''I''' |
||
| |
| |
||
|- |
|- |
||
| |
|F '''77''' '''L''' |
||
| |
| |
||
|- |
|- |
||
| |
|F '''116''' '''Y''' |
||
| |
| |
||
|- |
|- |
||
| |
|Q '''151''' '''M''' |
||
| |
| |
||
|- |
|- |
||
| rowspan=6 | |
| rowspan="6" |Thymidine analogue-associated mutations (TAMs) multi-NRTI resistance |
||
| |
|M '''41''' '''L''' |
||
| rowspan=6 | |
| rowspan="6" |resistance to AZT and d4T; resistance to others is proportional to the number of TAMs |
||
|- |
|- |
||
| |
|D '''67''' '''N''' |
||
|- |
|- |
||
| |
|K '''70''' '''R''' |
||
|- |
|- |
||
| |
|L '''210''' '''W''' |
||
|- |
|- |
||
| |
|T '''215''' '''Y F''' |
||
|- |
|- |
||
| |
|K '''219''' '''Q W''' |
||
|- |
|- |
||
| rowspan=4 | |
| rowspan="4" |[[Abacavir]] |
||
| |
|K '''65''' '''R E N''' |
||
| |
| |
||
|- |
|- |
||
| |
|L '''74''' '''V''' |
||
| |
| |
||
|- |
|- |
||
| |
|Y '''115''' '''F''' |
||
| |
| |
||
|- |
|- |
||
| |
|M '''184''' '''V''' |
||
| |
|common; can still use TDF, AZT |
||
|- |
|- |
||
| rowspan=2 | |
| rowspan="2" |[[Emtricitabine]] |
||
| |
|K '''65''' '''R E N''' |
||
| |
| |
||
|- |
|- |
||
| |
|M '''184''' '''V I''' |
||
| |
|common; can use ABC (if M184I), TDF, AZT; can still use FTC in combination with TDF or TAF |
||
|- |
|- |
||
| rowspan=2 | |
| rowspan="2" |[[Lamivudine]] |
||
| |
|K '''65 '''R E N |
||
| |
| |
||
|- |
|- |
||
| |
|M '''184''' '''V I''' |
||
| |
|common; can use ABC (if M184I), TDF, AZT; can still use 3TC in combination with TDF or TAF |
||
|- |
|- |
||
| rowspan=2 | |
| rowspan="2" |[[Tenofovir]] |
||
| |
|K '''65''' '''R E N''' |
||
| |
| |
||
|- |
|- |
||
| |
|K '''70''' '''E''' |
||
| |
| |
||
|- |
|- |
||
| rowspan=6 | |
| rowspan="6" |[[Zidovudine]] |
||
| |
|M '''41''' '''L''' |
||
| |
| |
||
|- |
|- |
||
| |
|D '''67''' '''N''' |
||
| |
| |
||
|- |
|- |
||
| |
|K '''70''' '''R''' |
||
| |
| |
||
|- |
|- |
||
| |
|L '''210''' '''W''' |
||
| |
| |
||
|- |
|- |
||
| |
|T '''215''' '''Y F''' |
||
| |
| |
||
|- |
|- |
||
| |
|K '''219''' '''Q E''' |
||
| |
| |
||
|- |
|- |
||
! colspan=3 | |
! colspan="3" |NNRTIs |
||
|- |
|- |
||
| rowspan=7 | |
| rowspan="7" |[[Doravirine]] |
||
| |
|V '''106''' '''A''' I '''M''' T |
||
| |
| |
||
|- |
|- |
||
| |
|Y '''188''' C '''L''' H |
||
| |
| |
||
|- |
|- |
||
| |
|G '''190''' E |
||
| |
| |
||
|- |
|- |
||
| |
|P '''225''' H |
||
| |
| |
||
|- |
|- |
||
| |
|F '''227''' C L R |
||
| |
| |
||
|- |
|- |
||
| |
|M '''230''' L |
||
| |
| |
||
|- |
|- |
||
| |
|L '''234''' I |
||
| |
| |
||
|- |
|- |
||
| rowspan=10 | |
| rowspan="10" |[[Efavirenz]] |
||
| |
|L '''100''' '''I''' |
||
| |
| |
||
|- |
|- |
||
| |
|K '''101''' '''P''' |
||
| |
| |
||
|- |
|- |
||
| |
|K '''103''' '''N S''' |
||
| |
| |
||
|- |
|- |
||
| |
|V '''106''' '''M''' |
||
| |
| |
||
|- |
|- |
||
| |
|V '''108''' '''I''' |
||
| |
| |
||
|- |
|- |
||
| |
|Y '''181''' '''C I''' |
||
| |
| |
||
|- |
|- |
||
| |
|Y '''188''' '''L''' |
||
| |
| |
||
|- |
|- |
||
| |
|G '''190''' '''S A''' |
||
| |
| |
||
|- |
|- |
||
| |
|P '''225''' '''H''' |
||
| |
| |
||
|- |
|- |
||
| |
|M '''230''' '''L''' |
||
| |
| |
||
|- |
|- |
||
| rowspan=9 | |
| rowspan="9" |[[Nevirapine]] |
||
| |
|L '''100''' '''I''' |
||
| |
| |
||
|- |
|- |
||
| |
|K '''101''' '''P''' |
||
| |
| |
||
|- |
|- |
||
| |
|K '''103''' '''N S''' |
||
| |
| |
||
|- |
|- |
||
| |
|V '''106''' '''A M''' |
||
| |
| |
||
|- |
|- |
||
| |
|V '''108''' '''I''' |
||
| |
| |
||
|- |
|- |
||
| |
|Y '''181''' '''C I''' |
||
| |
| |
||
|- |
|- |
||
| |
|Y '''188''' '''C L H''' |
||
| |
| |
||
|- |
|- |
||
| |
|G '''190''' '''A''' |
||
| |
| |
||
|- |
|- |
||
| |
|M '''230''' '''L''' |
||
| |
| |
||
|- |
|- |
||
| rowspan=9 | |
| rowspan="9" |[[Rilpivirine]] |
||
| |
|L '''100''' '''I''' |
||
| |
| |
||
|- |
|- |
||
| |
|K '''101''' '''E P''' |
||
| |
| |
||
|- |
|- |
||
| |
|E '''138''' '''A G K Q R''' |
||
| |
| |
||
|- |
|- |
||
| |
|V '''179''' '''L''' |
||
| |
| |
||
|- |
|- |
||
| |
|Y '''181''' '''C I V''' |
||
| |
| |
||
|- |
|- |
||
| |
|Y '''188''' '''L''' |
||
| |
| |
||
|- |
|- |
||
| |
|H '''221''' '''Y''' |
||
| |
| |
||
|- |
|- |
||
| |
|F '''227''' '''C''' |
||
| |
| |
||
|- |
|- |
||
| |
|M '''230''' '''I L''' |
||
| |
| |
||
|- |
|- |
||
! colspan=3 | |
! colspan="3" |Protease inhibitors |
||
|- |
|- |
||
| rowspan=24 | |
| rowspan="24" |[[Atazanavir]] |
||
| |
|L '''10''' I F V C |
||
| |
| |
||
|- |
|- |
||
| |
|G '''16''' E |
||
| |
| |
||
|- |
|- |
||
| |
|K '''20''' R M I T V |
||
| |
| |
||
|- |
|- |
||
| |
|L '''24''' I |
||
| |
| |
||
|- |
|- |
||
| |
|V '''32''' I |
||
| |
| |
||
|- |
|- |
||
| |
|L '''33''' I F V |
||
| |
| |
||
|- |
|- |
||
| |
|E '''34''' Q |
||
| |
| |
||
|- |
|- |
||
| |
|M '''36''' I L V |
||
| |
| |
||
|- |
|- |
||
| |
|M '''46''' I L |
||
| |
| |
||
|- |
|- |
||
| |
|G '''48''' V |
||
| |
| |
||
|- |
|- |
||
| |
|I '''50''' '''L''' |
||
| |
| |
||
|- |
|- |
||
| |
|F '''53''' L Y |
||
| |
| |
||
|- |
|- |
||
| |
|I '''54''' L V M T A |
||
| |
| |
||
|- |
|- |
||
| |
|D '''60''' E |
||
| |
| |
||
|- |
|- |
||
| |
|I '''62''' V |
||
| |
| |
||
|- |
|- |
||
| |
|I '''64''' L M V |
||
| |
| |
||
|- |
|- |
||
| |
|A '''71''' V I T L |
||
| |
| |
||
|- |
|- |
||
| |
|G '''73''' C S T A |
||
| |
| |
||
|- |
|- |
||
| |
|V 82 A T F I |
||
| |
| |
||
|- |
|- |
||
| |
|I '''84''' '''V''' |
||
| |
| |
||
|- |
|- |
||
| |
|I 85 V |
||
| |
| |
||
|- |
|- |
||
| |
|N '''88''' '''S''' |
||
| |
| |
||
|- |
|- |
||
| |
|L 90 M |
||
| |
| |
||
|- |
|- |
||
| |
|I 93 L M |
||
| |
| |
||
|- |
|- |
||
| rowspan=10 | |
| rowspan="10" |[[Darunavir]] |
||
| |
|V 11 I |
||
| |
| |
||
|- |
|- |
||
| |
|V 32 I |
||
| |
| |
||
|- |
|- |
||
| |
|L 33 F |
||
| |
| |
||
|- |
|- |
||
| |
|I '''47''' '''V''' |
||
| |
| |
||
|- |
|- |
||
| |
|I '''50''' '''V''' |
||
| |
| |
||
|- |
|- |
||
| |
|I '''54''' '''M L''' |
||
| |
| |
||
|- |
|- |
||
| |
|T 74 P |
||
| |
| |
||
|- |
|- |
||
| |
|L '''76''' '''V''' |
||
| |
| |
||
|- |
|- |
||
| |
|I '''84''' '''V''' |
||
| |
| |
||
|- |
|- |
||
| |
|L 89 V |
||
| |
| |
||
|- |
|- |
||
! colspan=3 | |
! colspan="3" |INSTIs |
||
|- |
|- |
||
| rowspan=5 | |
| rowspan="5" |[[Bictegravir]] |
||
| |
|G 118 R |
||
| |
| |
||
|- |
|- |
||
| |
|E 138 K |
||
| |
| |
||
|- |
|- |
||
| |
|G 140 S |
||
| |
| |
||
|- |
|- |
||
| |
|Q '''148''' '''H''' |
||
| |
| |
||
|- |
|- |
||
| |
|R '''263''' '''K''' |
||
| |
| |
||
|- |
|- |
||
| rowspan=8 | |
| rowspan="8" |[[Cabotegravir]] |
||
| |
|T 66 K |
||
| |
| |
||
|- |
|- |
||
| |
|G '''118''' '''R''' |
||
| |
| |
||
|- |
|- |
||
| |
|E 138 A K T |
||
| |
| |
||
|- |
|- |
||
| |
|G '''140''' A C '''R''' S |
||
| |
| |
||
|- |
|- |
||
| |
|Q '''148''' '''H K R''' |
||
| |
| |
||
|- |
|- |
||
| |
|S 153 F Y |
||
| |
| |
||
|- |
|- |
||
| |
|N 155 H |
||
| |
| |
||
|- |
|- |
||
| |
|R '''263''' '''K''' |
||
| |
| |
||
|- |
|- |
||
| rowspan=7 | |
| rowspan="7" |[[Dolutegravir]] |
||
| |
|G '''118''' '''R''' |
||
| |
| |
||
|- |
|- |
||
| |
|F 121 Y |
||
| |
| |
||
|- |
|- |
||
| |
|E 138 A K T |
||
| |
| |
||
|- |
|- |
||
| |
|G 140 A S |
||
| |
| |
||
|- |
|- |
||
| |
|Q '''148''' '''H K R''' |
||
| |
| |
||
|- |
|- |
||
| |
|N 155 H |
||
| |
| |
||
|- |
|- |
||
| |
|R '''263''' '''K''' |
||
| |
| |
||
|- |
|- |
||
| rowspan=8 | |
| rowspan="8" |[[Elvitegravir]] |
||
| |
|T '''66''' '''I''' A K |
||
| |
| |
||
|- |
|- |
||
| |
|E '''92''' '''Q''' G |
||
| |
| |
||
|- |
|- |
||
| |
|T 97 A |
||
| |
| |
||
|- |
|- |
||
| |
|F '''121''' '''Y''' |
||
| |
| |
||
|- |
|- |
||
| |
|S '''147''' '''G''' |
||
| |
| |
||
|- |
|- |
||
| |
|Q '''148''' '''H K R''' |
||
| |
| |
||
|- |
|- |
||
| |
|N '''155''' '''H''' |
||
| |
| |
||
|- |
|- |
||
| |
|R '''263''' '''K''' |
||
| |
| |
||
|- |
|- |
||
| rowspan=10 | |
| rowspan="10" |[[Raltegravir]] |
||
| |
|L 74 M |
||
| |
| |
||
|- |
|- |
||
| |
|E 92 Q |
||
| |
| |
||
|- |
|- |
||
| |
|T 97 A |
||
| |
| |
||
|- |
|- |
||
| |
|F '''121''' '''Y''' |
||
| |
| |
||
|- |
|- |
||
| |
|E 138 A K |
||
| |
| |
||
|- |
|- |
||
| |
|G 140 A S |
||
| |
| |
||
|- |
|- |
||
| |
|Y '''143''' '''R H C''' |
||
| |
| |
||
|- |
|- |
||
| |
|Q '''148''' '''H K R''' |
||
| |
| |
||
|- |
|- |
||
| |
|N '''155''' '''H''' |
||
| |
| |
||
|- |
|- |
||
| |
|R '''263''' '''K''' |
||
| |
| |
||
|} |
|} |
||
Revision as of 11:56, 28 August 2020
- Genotyping sequences reverse transcriptase, integrase, and protease
- Resistance point mutations names as wild-type amino acid, position, and mutant amino acid (e.g. K 103 N)
- Bulk sequencing can only detect mutations that represent >20% of HIV
| Drug | Mutation | Notes |
|---|---|---|
| NRTIs | ||
| 69 insertion complex multi-NRTI resistance | M 41 L | |
| A 62 V | ||
| * 69 insert | ||
| K 70 R | ||
| L 210 W | ||
| T 215 Y F | ||
| K 219 Q E | ||
| 151 complex multi-NRTI resistance | A 62 V | |
| V 75 I | ||
| F 77 L | ||
| F 116 Y | ||
| Q 151 M | ||
| Thymidine analogue-associated mutations (TAMs) multi-NRTI resistance | M 41 L | resistance to AZT and d4T; resistance to others is proportional to the number of TAMs |
| D 67 N | ||
| K 70 R | ||
| L 210 W | ||
| T 215 Y F | ||
| K 219 Q W | ||
| Abacavir | K 65 R E N | |
| L 74 V | ||
| Y 115 F | ||
| M 184 V | common; can still use TDF, AZT | |
| Emtricitabine | K 65 R E N | |
| M 184 V I | common; can use ABC (if M184I), TDF, AZT; can still use FTC in combination with TDF or TAF | |
| Lamivudine | K 65 R E N | |
| M 184 V I | common; can use ABC (if M184I), TDF, AZT; can still use 3TC in combination with TDF or TAF | |
| Tenofovir | K 65 R E N | |
| K 70 E | ||
| Zidovudine | M 41 L | |
| D 67 N | ||
| K 70 R | ||
| L 210 W | ||
| T 215 Y F | ||
| K 219 Q E | ||
| NNRTIs | ||
| Doravirine | V 106 A I M T | |
| Y 188 C L H | ||
| G 190 E | ||
| P 225 H | ||
| F 227 C L R | ||
| M 230 L | ||
| L 234 I | ||
| Efavirenz | L 100 I | |
| K 101 P | ||
| K 103 N S | ||
| V 106 M | ||
| V 108 I | ||
| Y 181 C I | ||
| Y 188 L | ||
| G 190 S A | ||
| P 225 H | ||
| M 230 L | ||
| Nevirapine | L 100 I | |
| K 101 P | ||
| K 103 N S | ||
| V 106 A M | ||
| V 108 I | ||
| Y 181 C I | ||
| Y 188 C L H | ||
| G 190 A | ||
| M 230 L | ||
| Rilpivirine | L 100 I | |
| K 101 E P | ||
| E 138 A G K Q R | ||
| V 179 L | ||
| Y 181 C I V | ||
| Y 188 L | ||
| H 221 Y | ||
| F 227 C | ||
| M 230 I L | ||
| Protease inhibitors | ||
| Atazanavir | L 10 I F V C | |
| G 16 E | ||
| K 20 R M I T V | ||
| L 24 I | ||
| V 32 I | ||
| L 33 I F V | ||
| E 34 Q | ||
| M 36 I L V | ||
| M 46 I L | ||
| G 48 V | ||
| I 50 L | ||
| F 53 L Y | ||
| I 54 L V M T A | ||
| D 60 E | ||
| I 62 V | ||
| I 64 L M V | ||
| A 71 V I T L | ||
| G 73 C S T A | ||
| V 82 A T F I | ||
| I 84 V | ||
| I 85 V | ||
| N 88 S | ||
| L 90 M | ||
| I 93 L M | ||
| Darunavir | V 11 I | |
| V 32 I | ||
| L 33 F | ||
| I 47 V | ||
| I 50 V | ||
| I 54 M L | ||
| T 74 P | ||
| L 76 V | ||
| I 84 V | ||
| L 89 V | ||
| INSTIs | ||
| Bictegravir | G 118 R | |
| E 138 K | ||
| G 140 S | ||
| Q 148 H | ||
| R 263 K | ||
| Cabotegravir | T 66 K | |
| G 118 R | ||
| E 138 A K T | ||
| G 140 A C R S | ||
| Q 148 H K R | ||
| S 153 F Y | ||
| N 155 H | ||
| R 263 K | ||
| Dolutegravir | G 118 R | |
| F 121 Y | ||
| E 138 A K T | ||
| G 140 A S | ||
| Q 148 H K R | ||
| N 155 H | ||
| R 263 K | ||
| Elvitegravir | T 66 I A K | |
| E 92 Q G | ||
| T 97 A | ||
| F 121 Y | ||
| S 147 G | ||
| Q 148 H K R | ||
| N 155 H | ||
| R 263 K | ||
| Raltegravir | L 74 M | |
| E 92 Q | ||
| T 97 A | ||
| F 121 Y | ||
| E 138 A K | ||
| G 140 A S | ||
| Y 143 R H C | ||
| Q 148 H K R | ||
| N 155 H | ||
| R 263 K | ||